Skip to content

Misrepresentation of MDMA in the United States, 1999-2023.

Eric L Sevigny, Sylvia Thyssen, Earth Erowid, Russell Lea

Drug and alcohol dependence November 1, 2024 DOI: 10.1016/j.drugalcdep.2024.112467 via PubMed

Summary

AI-generated from the abstract

Between 1999 and 2023, 4719 samples submitted as MDMA to the DrugsData drug checking service were analyzed. While 75% of users expected their sample to contain only MDMA, only 48% actually contained MDMA alone. The proportion of MDMA-only samples declined sharply from 57.4% in 1999 to 15.2% in 2009, then recovered to 56.0% by 2017, and rose more moderately to 74.1% by 2023. Across the 25-year period, 199 unique adulterants were detected. Trends in adulterant prevalence matched those seen in law enforcement seizure data. Although more than half of MDMA samples were misrepresented in some way, MDMA quality has stabilized at relatively high levels in recent years.

Study at a glance

Characteristics Observational study Peer reviewed
Sample size 4,719
Population Alleged MDMA samples submitted to a drug checking service
Duration 1999-2023
Topics MDMA
Keywords Safe supply Drug checking services MDMA Adulteration Harm reduction Substance testing
Citations 5
Key finding Only 48% of alleged MDMA samples contained MDMA alone, but MDMA-only prevalence recovered from a low of 15.2% in 2009 to 74.1% in 2023.

Abstract

The misrepresentation of illicit drugs in unregulated markets increases the risk of adverse health events. This study analyzed drug checking data to compare represented, expected, and actual content of alleged MDMA samples, estimate trends in the quality of the MDMA supply, document the presence of adulterants, compare patterns of adulteration, and validate drug checking against law enforcement data. The study analyzed 4719 alleged MDMA samples submitted to the DrugsData drug checking service between 1999-2023. Measures captured characteristics and quality of the MDMA supply, including represented content, expected and actual content, sample form, and specific adulterants. Tests of association were conducted using Pearson's chi-square or Spearman's rho, and tests for trends were performed using joinpoint regression. Most samples (75 %) were expected to contain MDMA, but this varied significantly by represented content (p<0.001). About half the samples (48 %) contained MDMA-only, which also varied significantly by represented content (p<0.001). MDMA-only prevalence declined from 1999-2009 (57.4-15.2 %, p<0.05), recovered from 2009-2017 (15.2-56.0 %, p<0.05), and increased more moderately from 2017-2023 (56.0-74.1 %, p<0.05). Overall, 199 unique adulterants were detected in the MDMA supply across 25 years. We confirmed robust correlations in adulterant prevalence trends between drug checking and law enforcement seizure data. While users typically expected alleged MDMA samples to contain only MDMA, more than half of the submitted MDMA samples were misrepresented in some manner. Despite high levels of misrepresentation, MDMA quality has stabilized at relatively high levels in recent years.

Explore topics

Comments

No comments yet.

Log in to comment